Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model

Atherosclerosis

Volumn 205, Issue 1, 2009, Pages 74-79

  Ge, Song ^a   Zhou, Guangyi ^a   Cheng, Songming ^a   Liu, Dezhi ^a   Xu, Jian ^a   Xu, Gelin ^a   Liu, Xinfeng ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Atherosclerosis; Atorvastatin; Monocyte chemotactic protein 1; Montelukast

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONTELUKAST; PLACEBO; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CAROTID ARTERY INJURY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SMOOTH MUSCLE FIBER; TRIACYLGLYCEROL BLOOD LEVEL;

ACETATES; ANIMALS; ATHEROSCLEROSIS; BALLOON DILATATION; CAROTID ARTERIES; CHEMOKINE CCL2; DIET, ATHEROGENIC; DISEASE PROGRESSION; HEPTANOIC ACIDS; IMMUNOHISTOCHEMISTRY; LEUKOTRIENE ANTAGONISTS; LIPIDS; MALE; PYRROLES; QUINOLINES; RABBITS; RANDOM ALLOCATION;

EID: 67349098843     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.11.012     Document Type: Article

References (30)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (1999) 115-126
2. Samuelsson B., Dahlén S.E., Lindgren J.A., Rouzer C.A., and Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 4819 (1987) 1171-1176
3. Bäck M. Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle. Acta Physiol Scand Suppl 648 (2002) 1-55
4. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 5548 (2001) 1871-1875
5. Cipollone F., Mezzetti A., Fazia M.L., et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 25 8 (2005) 1665-1670
6. Qiu H., Gabrielsen A., Agardh H.E., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 103 21 (2006) 8161-8166
7. Spanbroek R., Grabner R., Lotzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100 3 (2003) 1238-1243
8. Lötzer K., Spanbroek R., Hildner M., et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 23 8 (2003) e32-e36
9. Zhao L., Moos M.P., Gräbner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 9 (2004) 966-973
10. Ichiyama T., Hasegawa M., Ueno Y., et al. Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages. Clin Exp Allergy 35 9 (2005) 1214-1219
11. Dahlén S.E. Treatment of asthma with antileukotrienes: first line or last resort therapy?. Eur J Pharmacol 533 1-3 (2006) 40-56
12. Sener G., Kabasakal L., Cetinel S., et al. Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs. Burns 31 5 (2005) 87-96
13. Sener G., Sehirli O., Cetinel S., et al. Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast. Prostoglandins Leukot Essent Fatty Acids 73 6 (2005) 453-462
14. Sener G., Sehirli O., Velioǧlu-Oǧünç A., et al. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res 54 1 (2006) 573-579
15. Bäck M., Airila-Månsson S., Jogestrand T., et al. Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. Atherosclerosis 193 2 (2006) 389-394
16. Kamohara M., Takasaki J., Matsumoto M., et al. Functional characterization of cysteinyl leukotriene CysLT2 receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun 287 5 (2001) 1088-1092
17. Lusis A.J., Mar R., and Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 5 (2004) 189-218
18. Clarke M., and Bennett M. The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol 26 6 (2006) 531-535
19. Baetta R., Donetti E., Comparato C., et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 36 2 (1997) 115-121
20. Herdeg C., Fitzke M., Oberhoff M., et al. Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. Int J Cardiol 91 1 (2003) 59-69
21. Nicholls S.J., Cutri B., Worthley S.G., et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25 11 (2005) 2416-2421
22. Kaetsu Y., Yamamoto Y., Sugihara S., et al. Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro. Cardiovasc Res 76 1 (2007) 160-166
23. Boisvert W.A. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 14 (2004) 161-165
24. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 95 (2004) 858-866
25. Chen Y.L., Chang Y.J., and Jiang M.J. Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits. Atherosclerosis 143 1 (1999) 115-123
26. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
27. Calabrò P., and Yeh E.T. The pleiotropic effects of statins. Curr Opin Cardiol 20 6 (2005) 541-546
28. Kronmann L., Hatfield C., and Kronmann K. Statin therapy: not just used to lower cholesterol?. Crit Care Nurs Q 30 2 (2007) 154-160
29. Ortego M., Bustos C., Hernandez-Presa M.A., et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147 2 (1999) 253-261
30. Bustos C., Hernández-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 7 (1998) 2057-2064